79 related articles for article (PubMed ID: 1657088)
1. Antitumor ether lipids: endocytosis as a determinant of cellular sensitivity.
Workman P
Cancer Cells; 1991 Aug; 3(8):315-7. PubMed ID: 1657088
[No Abstract] [Full Text] [Related]
2. [Platelet-activating factor (PAF) antagonists].
Terasawa M
Tanpakushitsu Kakusan Koso; 1991 Feb; 36(3):379-87. PubMed ID: 1850862
[No Abstract] [Full Text] [Related]
3. Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells.
Bazill GW; Dexter TM
Cancer Res; 1990 Dec; 50(23):7505-12. PubMed ID: 2253199
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of cell signaling pathways by antitumor ether lipids.
Arthur G; Bittman R
Biochim Biophys Acta; 1998 Feb; 1390(1):85-102. PubMed ID: 9487143
[No Abstract] [Full Text] [Related]
5. Antitumor activity of a piperidine phospholipid.
Houlihan WJ; Lee ML; Munder PG; Handley DA; Nemecek GA; Jaeggi CS; Winslow CW
Arzneimittelforschung; 1994 Dec; 44(12):1384-8. PubMed ID: 7848363
[TBL] [Abstract][Full Text] [Related]
6. An antagonist to platelet activating factor counteracts the tumoricidal action of alkyl lysophospholipids.
Bazill GW; Dexter TM
Biochem Pharmacol; 1989 Jan; 38(2):374-7. PubMed ID: 2536543
[No Abstract] [Full Text] [Related]
7. Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells.
Dive C; Watson JV; Workman P
Cancer Res; 1991 Feb; 51(3):799-806. PubMed ID: 1988120
[TBL] [Abstract][Full Text] [Related]
8. The effect of ether lipid 1-O-octadecyl-2-O-methoxy-rac-glycero-3-phosphocholine and its analogues platelet activating factor and carbamyl-platelet activating factor on the biosynthesis of interleukin-6 in human thymic epithelial cells cultivated in vitro.
Cardile V; Mascarucci P; De Simoni MG; Jiang X; Bindoni M
Cytokine; 1996 Sep; 8(9):698-701. PubMed ID: 8932980
[TBL] [Abstract][Full Text] [Related]
9. A platelet-activating factor receptor antagonist protects against renal function deterioration in nephrotoxic nephritis.
Livio M; Macconi D; Morigi M; Orisio S; Benigni A; Patrono C; Remuzzi G
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17B():828-32. PubMed ID: 2823570
[No Abstract] [Full Text] [Related]
10. Antitumor activity of SRI 62-834, a cyclic ether analog of ET-18-OCH3.
Houlihan WJ; Lee ML; Munder PG; Nemecek GM; Handley DA; Winslow CM; Happy J; Jaeggi C
Lipids; 1987 Nov; 22(11):884-90. PubMed ID: 2832680
[TBL] [Abstract][Full Text] [Related]
11. Ether lipids in the therapy of cancer.
Andreesen R
Prog Biochem Pharmacol; 1988; 22():118-31. PubMed ID: 3043427
[No Abstract] [Full Text] [Related]
12. Sensitivity of K562 and HL-60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen species.
Wagner BA; Buettner GR; Oberley LW; Burns CP
Cancer Res; 1998 Jul; 58(13):2809-16. PubMed ID: 9661895
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
Houlihan WJ; Prasad K; Underwood R; Repic O; Munder PG
J Med Chem; 1996 Jan; 39(2):605-8. PubMed ID: 8558533
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate, a specific PAF antagonist, in endotoxin and anaphylactic shock.
Terashita Z; Imura Y; Nishikawa K; Sumida S
Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():715-7. PubMed ID: 3004156
[No Abstract] [Full Text] [Related]
15. Desensitization of platelet-activating factor-stimulated protein phosphorylation in platelets.
Shukla SD; Morrison WJ; Dhar A
Mol Pharmacol; 1989 Apr; 35(4):409-13. PubMed ID: 2539556
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of some benzyl and benzylidene monosubstituted gamma-butyrolactones and tetrahydrofurans as platelet activating factor antagonist agents.
Coran SA; Giannellini V; Bambagiotti-Alberti M; Moriggi E; Sala R; Valle G
Farmaco; 1995; 50(7-8):511-8. PubMed ID: 7669189
[TBL] [Abstract][Full Text] [Related]
17. [The significance of platelet activating factor and its antagonists in bronchial asthma].
Beume R; Kilian U
Med Klin (Munich); 1989 Jun; 84(6):286-93. PubMed ID: 2547143
[No Abstract] [Full Text] [Related]
18. The role of intracellular free calcium mobilization in the mechanism of action of antitumour ether lipids SRI 62-834 and ET18-OMe.
Lohmeyer M; Workman P
Biochem Pharmacol; 1993 Jan; 45(1):77-86. PubMed ID: 8424826
[TBL] [Abstract][Full Text] [Related]
19. Receptor-mediated and protein kinase-dependent growth enhancement of primary human fibroblasts by platelet activating factor.
Bennett SA; Birnboim HC
Mol Carcinog; 1997 Dec; 20(4):366-75. PubMed ID: 9433481
[TBL] [Abstract][Full Text] [Related]
20. Elevation of leukemic cell intracellular calcium by the ether lipid SRI 62-834.
Lazenby CM; Thompson MG; Hickman JA
Cancer Res; 1990 Jun; 50(11):3327-30. PubMed ID: 2334926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
